Clinical Trials
16 trialsNCT03903705 2025-04-06
: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors
Hutchmed
Phase 1/2 Completed
NCT04322539 2025-04-04
FRESCO-2
Hutchmed
Phase 3 Completed
NCT04716634 2025-03-25
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
BeiGene
Phase 2 Completed
NCT03251378 2024-09-25
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
Hutchmed
Phase 1 Completed
NCT06202599 2024-01-17
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance
Peking University People's Hospital
Completed
NCT06202417 2024-01-11
Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study
Fudan University
Completed
NCT06031376 2023-09-11
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Hunan Cancer Hospital
Completed
NCT05025631 2023-04-28
DOFEMCRC
Sichuan University
Phase 2 Completed
NCT05368805 2022-10-06
Fruquintinib DDI Study With P-gp and BCRP Substrates
Hutchmed
Phase 1 Completed
NCT02196688 2020-06-16
Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
Hutchmed
Phase 2 Completed
NCT01645215 2020-02-17
Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors
Hutchmed
Phase 1 Completed
NCT01975077 2020-02-17
A Phase Ib Study of Fruquintinib in 3rd Line mCRC
Hutchmed
Phase 1/2 Completed
NCT02314819 2020-02-17
FRESCO
Hutchmed
Phase 3 Completed
NCT02590965 2020-02-13
A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
Hutchmed
Phase 2 Completed
NCT02976116 2019-11-15
A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
Hutchmed
Phase 2 Completed
NCT02691299 2019-02-12
FALUCA
Hutchmed
Phase 3 Completed